Bristol-Myers Squibb Files Second Quarter 10-Q With SEC
The pharmaceutical giant submitted its quarterly report to regulators as investors await third-quarter earnings in late October.
Quarterly Filing Submitted
Bristol-Myers Squibb Company filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on July 30, according to regulatory filings. The submission provides investors with the pharmaceutical company's financial performance and operational updates for the second quarter of 2026.
The New York-based drugmaker, which closed at $64.86 in its most recent trading session, maintains a market capitalization of approximately $132 billion, positioning it among the largest pharmaceutical companies in the United States.
Recent Insider Activity
According to MarginX data, the company has recorded recent insider awards to several executives. Theodore R. Samuels II received an award of 889.448 shares, while Derica W. Rice was awarded 672.51 shares and Michael R. McMullen received 607.428 shares. These awards typically represent equity-based compensation aligned with standard executive remuneration practices at large pharmaceutical companies.
Looking Ahead
Investors will have limited time to digest the second-quarter filing before attention turns to the company's third-quarter results. Bristol-Myers Squibb is scheduled to report Q3 2026 earnings on October 29, with a corresponding earnings call planned for the same day, according to MarginX data.
The timing of that announcement coincides with a Federal Open Market Committee rate decision scheduled for October 28, creating a potentially eventful period for market participants. An earlier FOMC meeting is scheduled for September 16, which will include both a rate decision and economic projections that could influence investor sentiment toward large-cap pharmaceutical stocks.
The 10-Q filing represents standard quarterly disclosure requirements for publicly traded companies, providing detailed financial statements, management discussion and analysis, and information about market risks and legal proceedings. Investors and analysts typically scrutinize these filings for insights into revenue trends, research and development progress, and strategic priorities.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.